NeoGenomics, Inc.

NasdaqCM:NEO 株式レポート

時価総額:US$1.7b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

NeoGenomics マネジメント

マネジメント 基準チェック /24

NeoGenomics'の CEO はChris Smithで、 Aug2022年に任命され、 の在任期間は 1.83年です。 の年間総報酬は$ 11.67Mで、 8.6%給与と91.4%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.53%を直接所有しており、その価値は$ 8.90M 。経営陣と取締役会の平均在任期間はそれぞれ1.7年と3.4年です。

主要情報

Chris Smith

最高経営責任者

US$11.7m

報酬総額

CEO給与比率8.6%
CEO在任期間1.8yrs
CEOの所有権0.5%
経営陣の平均在職期間1.7yrs
取締役会の平均在任期間3.4yrs

経営陣の近況

Recent updates

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Mar 30
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Dec 26
Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Aug 23
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16
Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18
NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10
We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22
Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11
Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07
Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

NeoGenomics: Gambling On Growth

Dec 16

NeoGenomics: Profitability Headwinds Compress Valuation, Shares

Sep 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Sep 24
Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

NeoGenomics: Strong Growth Potential For A Leader In Cancer Diagnostic Testing

Jul 02

NeoGenomics completes Inivata acquisition

Jun 18

CEO報酬分析

NeoGenomics の収益と比較して、Chris Smith の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$84m

Dec 31 2023US$12mUS$1m

-US$88m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$115m

Mar 31 2023n/an/a

-US$126m

Dec 31 2022US$15mUS$346k

-US$144m

報酬と市場: Chrisの 総報酬 ($USD 11.67M ) は、 US市場 ($USD 5.67M ) の同規模の企業の平均を上回っています。

報酬と収益: Chrisの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Chris Smith (61 yo)

1.8yrs

在職期間

US$11,665,946

報酬

Mr. Christopher Michael Smith, also known as Chris, serves as Chief Executive Officer at NeoGenomics Laboratories, Inc. since August 2022. He serves as Director at NeoGenomics Laboratories, Inc. since 2023...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Christopher Smith
CEO & Director1.8yrsUS$11.67m0.53%
$ 8.9m
Jeffrey Sherman
Chief Financial Officer1.5yrsUS$3.55m0.12%
$ 2.0m
Vishal Sikri
President of Advanced Diagnostics2.4yrsUS$2.37m0.10%
$ 1.7m
Melody Harris
President & COO of Informatics1.5yrsUS$4.69m0.085%
$ 1.4m
Warren Stone
Chief Commercial Officer1.6yrsUS$3.01m0.079%
$ 1.3m
Gregory Aunan
Chief Accounting Officer1.1yrsデータなし0.011%
$ 190.4k
Kendra Sweeney
Vice President of Investor Relations & Communicationsno dataデータなしデータなし
Alicia Olivo
Executive VP of Business Development2.2yrsデータなし0.035%
$ 590.9k
Hutan Hashemi
Chief Compliance Officer2.2yrsデータなしデータなし
Derek Lyle
Chief Medical Officer3.4yrsデータなしデータなし
Gary Passman
Chief Culture Officer1.4yrsデータなしデータなし
Fernando López-Díaz
Director of Clinical Scienceno dataデータなしデータなし

1.7yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: NEOの経営陣は 経験豊富 とはみなされません ( 1.7年の平均在職年数)。これは新しいチームを示唆しています。


取締役

名称ポジション在職期間報酬所有権
Christopher Smith
CEO & Director1.8yrsUS$11.67m0.53%
$ 8.9m
Michael Kelly
Independent Director3.9yrsUS$317.50k0.016%
$ 268.9k
Lynn Tetrault
Independent Chair of the Board9yrsUS$365.00k0.039%
$ 659.3k
Bernard Fox
Member of Scientific Advisory Board3.4yrsデータなしデータなし
Riccardo Dalla-Favera
Member of Scientific Advisory Board3.4yrsデータなしデータなし
Anthony Zook
Independent Directorless than a yearUS$276.23kデータなし
Steven Rosen
Member of Scientific Advisory Board3.4yrsデータなしデータなし
James Downing
Member of Scientific Advisory Board3.4yrsデータなしデータなし
Stephen Kanovsky
Independent Director6.9yrsUS$309.20k0.019%
$ 326.0k
Razelle Kurzrock
Member of Scientific Advisory Board3.4yrsデータなしデータなし
Alison Hannah
Member of Scientific Advisory Board & Independent Director9yrsUS$305.00k0.084%
$ 1.4m
Mark Rubin
Member of Scientific Advisory Board3.4yrsデータなしデータなし

3.4yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: NEOの 取締役会経験豊富 であると考えられます ( 3.4年の平均在任期間)。